2022-002191-36
A Study Comparing the Pharmacokinetics and Palatability of Two Candidate Pediatric Powder-for-Oral-Suspension Formulations of Maribavir to the Current Maribavir Tablet Formulation Administered in Healthy Adult Participants
Shire·EU Clinical Trials Register
Study focus
- Disease/Condition
- Healthy volunteers
Sponsor & location
- Primary sponsor
- Shire
Timeline & enrollment
- Phase
- N/A
- Start date
- N/A
- End date
- N/A
Primary outcome
- Part 1: Maximum Concentration (Cmax) Occurred at Time of Maximum Observed Concentration Sampled During a Dosing Interval (Tmax) of Maribavir in Plasma
ICD-10 classifications
Healthy person accompanying sick personRoutine general health check-up of armed forcesRoutine general health check-up of sports teamsRoutine general health check-up of inhabitants of institutions
Data source
- Registry
- EU Clinical Trials Register
- Trial ID
- 2022-002191-36
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for 2022-002191-36 through Pure Global AI's free database. This phase not specified trial is sponsored by Shire and is currently status unknown. The study focuses on Healthy volunteers.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.